James Hansbrough
Pulmonary Disease · Bowling Green, KYNPI 1255335006
Payments from drug & device makers
Across 618 payments — averaging $19.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pulmonx Corporation$2K
- AstraZeneca$2K
- Boehringer Ingelheim$1K
- GSK$1K
- Sanofi$643
- Actelion Pharmaceuticals US, Inc.$517
- plus $4K from 36 others
What the payments were for
- Consulting fees$2,25018%
- Food & beverage$9,76279%
- Education$3113%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEPHYR ENDOBRONCHIAL VALVE$2,250
- FASENRA$486
- BREZTRI$353
- FARXIGA$185
- TEZSPIRE$168
- SYMBICORT$132
- BREZTRI AEROSPHERE$132
- NUCALA$125
How this compares
$12,323 in reported general payments places this provider in the 75th percentile of 226 pulmonary disease providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Breo ElliptaFluticasone/Vilanterol | 11 | $5,088 |
| Advair HfaFluticasone Propion/Salmeterol | 13 | $4,092 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 33 | $887 |
| Montelukast Sodium | 21 | $118 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKBreo Ellipta | $1,392 | $5,08811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 226 pulmonary disease providers in Kentucky.
Other pulmonary disease in Bowling Green
- John McConnellLouisville$3.5M
- Girish NairLexington$852K
- Sally SulimanLouisville$472K
- Mohamed SaadLouisville$440K
- David WinslowLouisville$431K
- Firas KouraGeorgetown$423K
- Erica GregonisRichmond$390K
- Karim El-KershLouisville$379K
- Harold HallerLouisville$369K
- Steven KoenigMorehead$242K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.